Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
OwnerGarrett A. Fitzgerald, Lei Zhaoinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides, inter alia, inhibitors of cardiovascular diseases and disorders. The present invention also provides therapeutic methods for preventing and/or treating cardiovascular diseases and disorders. Further, the present invention provides methods of identifying inhibitors of cardiovascular diseases and disorders as well as model systems suitable for identifying such inhibitors as well as methods and compositions for detecting and/or diagnosing cardiovascular diseases and disorders.
Claims23
-16. (canceled)
A method of developing a prognosis for a subject who has been diagnosed with a cardiovascular disease or disorder comprising measuring levels of DP1 and/or DP2 in a sample from the subject and comparing the DP1 and/or DP2 levels to the DP1 and/or DP2 levels found in control subjects.
A method of identifying subjects at risk for aneurysm comprising measuring levels of DP1 and/or DP2 in a sample from a subject and comparing the DP1 and/or DP2 levels to DP1 and/or DP2 levels found in normal subjects, wherein elevated levels of DP1 and/or DP2 are indicative of an increased risk for aneurysm.
A method of imaging one or more aneurysms in a subject comprising:
- a) administering a probe, antibody or fragment thereof, or oligonucleotide that specifically binds to a DP1 or a DP2 receptor into the subject's vasculature;
- b) determining whether the probe, antibody or fragment thereof or oligonucleotide binds to the vasculature, wherein binding of the antibody to the vasculature is indicative of the presence of one or more aneurysms.
A method of inhibiting a cardiovascular disease or disorder in a subject in need thereof comprising administering to said patient an amount of a DP1 and/or DP2 receptor inhibitor effective to reduce collagen disruption in a vessel of the subject and/or an amount of a DP1 and/or DP2 receptor inhibitor effective to reduce elastin disruption in a vessel of the subject.
A method of inhibiting an aneurysm in a subject in need thereof comprising administering to the subject a therapeutically effective dose of one or more compounds selected from the group consisting of:
- PGD2 receptor inhibitors, inhibitors of MAP Kinase activation;
- MAP Kinase inhibitors;
- inhibitors of cytokine expression;
- and inhibitors of smooth muscle cell proliferation.
A method of inhibiting a symptom of aneurysm in a subject in need thereof comprising administering to the subject a therapeutically effective dose of one or more compounds selected from the group consisting of:
- PGD2 receptor inhibitors, Map Kinase inhibitors, inhibitors of Map kinase activation, DP1 and/or DP2 receptor inhibitors, and inhibitors of cytokine expression.
A method of inhibiting smooth muscle cell proliferation comprising in a subject in need thereof comprising administering to said patient a therapeutically effective amount of one or more compounds selected from the group consisting of:
- DP1 receptor antagonists, DP2 receptor antagonists and Map Kinase inhibitors.
A method for reducing blood pressure in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds selected from the group consisting of:
- PGD2 receptor inhibitors, Map Kinase inhibitors, inhibitors of Map kinase activation, DP1 and/or DP2 receptor inhibitors, and inhibitors of cytokine expression.
Dependencies are inferred from the claim text.